Moreover, a Bayesian network meta-analysis included information from direct and indirect comparisons of randomized controlled trials examining remission (DAS28-CRP < 2.6) and LDA (DAS28-CRP ≤ 3.2) after treatment with Tofacitinib, Baricitinib, Upadacitinib, Filgotinib monotherapy, and MTX in DMARD-naïve patients with RA. The gene discussed is CRP; the disease is rheumatoid arthritis.